INTRODUCTION: Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event associated with bone-modifying agents (BMAs) and affects patients in the terminal stages of cancer. Molecular targeting drugs (MTDs), anti-vascular endothelial growth factor receptor (VEGFR), and anti-epidermal growth factor receptor (EGFR) drugs are essential in various cancer treatments, although MTDs are risk factors for ARONJ. However, the mechanism through which MTDs affect treatment prognosis of ARONJ remains unclear. Therefore, we investigated the potential inhibitory factors for healing in the conservative therapy of ARONJ with a focus on MTDs. MATERIALS AND METHODS: Sixty patients who were administered BMAs for the treatment of malignancies and who underwent conservative treatment for ARONJ were assessed. The healing rate of ARONJ for each risk factor was retrospectively evaluated. RESULTS: Among the 60 patients, 27 were male and 33 were female. The median age was 67 years, and the median follow-up period was 292 (range 91-1758) days. The healing rate was lower in those treated with both zoledronic acid (Za) and denosumab (Dmab) than in those treated with Za or Dmab alone (0% vs. 28.8%, p = 0.03). Regarding the administration of MTDs, the treatment rate with anti-VEGFR drugs was 7.1% (p = 0.04), anti-EGFR drugs was 12.5% (p = 0.18), and without MTDs was 36.8%. CONCLUSION: In the conservative treatment of ARONJ, the administration of several BMAs and anti-VEGFR drugs was the factor contributing to the inhibition of healing.
INTRODUCTION: Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event associated with bone-modifying agents (BMAs) and affects patients in the terminal stages of cancer. Molecular targeting drugs (MTDs), anti-vascular endothelial growth factor receptor (VEGFR), and anti-epidermal growth factor receptor (EGFR) drugs are essential in various cancer treatments, although MTDs are risk factors for ARONJ. However, the mechanism through which MTDs affect treatment prognosis of ARONJ remains unclear. Therefore, we investigated the potential inhibitory factors for healing in the conservative therapy of ARONJ with a focus on MTDs. MATERIALS AND METHODS: Sixty patients who were administered BMAs for the treatment of malignancies and who underwent conservative treatment for ARONJ were assessed. The healing rate of ARONJ for each risk factor was retrospectively evaluated. RESULTS: Among the 60 patients, 27 were male and 33 were female. The median age was 67 years, and the median follow-up period was 292 (range 91-1758) days. The healing rate was lower in those treated with both zoledronic acid (Za) and denosumab (Dmab) than in those treated with Za or Dmab alone (0% vs. 28.8%, p = 0.03). Regarding the administration of MTDs, the treatment rate with anti-VEGFR drugs was 7.1% (p = 0.04), anti-EGFR drugs was 12.5% (p = 0.18), and without MTDs was 36.8%. CONCLUSION: In the conservative treatment of ARONJ, the administration of several BMAs and anti-VEGFR drugs was the factor contributing to the inhibition of healing.
Entities:
Keywords:
Antiresorptive-related osteonecrosis of the jaw; Conservative therapy; Endothelial growth factor receptor; Molecular targeting drug; Vascular endothelial growth factor receptor
Authors: Michael Gnant; Georg Pfeiler; Peter C Dubsky; Michael Hubalek; Richard Greil; Raimund Jakesz; Viktor Wette; Marija Balic; Ferdinand Haslbauer; Elisabeth Melbinger; Vesna Bjelic-Radisic; Silvia Artner-Matuschek; Florian Fitzal; Christian Marth; Paul Sevelda; Brigitte Mlineritsch; Günther G Steger; Diether Manfreda; Ruth Exner; Daniel Egle; Jonas Bergh; Franz Kainberger; Susan Talbot; Douglas Warner; Christian Fesl; Christian F Singer Journal: Lancet Date: 2015-05-31 Impact factor: 79.321
Authors: Noam Yarom; Charles L Shapiro; Douglas E Peterson; Catherine H Van Poznak; Kari Bohlke; Salvatore L Ruggiero; Cesar A Migliorati; Aliya Khan; Archie Morrison; Holly Anderson; Barbara A Murphy; Devena Alston-Johnson; Rui Amaral Mendes; Beth Michelle Beadle; Siri Beier Jensen; Deborah P Saunders Journal: J Clin Oncol Date: 2019-07-22 Impact factor: 44.544
Authors: Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl Journal: N Engl J Med Date: 2009-08-11 Impact factor: 91.245
Authors: F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey Journal: Ann Oncol Date: 2011-10-10 Impact factor: 32.976